Envista Holdings Corporation (NYSE:NVST) Receives $21.77 Consensus Target Price from Analysts

Shares of Envista Holdings Corporation (NYSE:NVST) have earned an average rating of “Hold” from the sixteen analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $21.7692.

Several equities research analysts have commented on NVST shares. Wall Street Zen upgraded Envista from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Barclays assumed coverage on shares of Envista in a report on Monday, December 8th. They set an “overweight” rating and a $24.00 target price for the company. Mizuho set a $19.00 target price on shares of Envista in a research report on Monday, November 3rd. Robert W. Baird set a $27.00 price target on shares of Envista in a research report on Friday, October 31st. Finally, Stifel Nicolaus set a $25.00 price objective on shares of Envista in a research note on Thursday, October 30th.

Envista Trading Up 0.0%

Shares of NYSE:NVST opened at $23.62 on Friday. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of 262.52, a PEG ratio of 1.05 and a beta of 0.99. Envista has a 12 month low of $14.22 and a 12 month high of $23.97. The company’s fifty day simple moving average is $21.06 and its 200 day simple moving average is $20.64. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last released its earnings results on Wednesday, October 29th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $669.90 million during the quarter, compared to analysts’ expectations of $639.49 million. Envista had a return on equity of 5.90% and a net margin of 0.58%.The company’s revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.12 EPS. As a group, research analysts forecast that Envista will post 1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC raised its stake in shares of Envista by 317.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock worth $27,000 after purchasing an additional 1,026 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after buying an additional 1,504 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after acquiring an additional 949 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Envista by 378.0% in the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock valued at $47,000 after acquiring an additional 1,909 shares during the last quarter. Finally, SJS Investment Consulting Inc. lifted its stake in Envista by 10,356.5% in the third quarter. SJS Investment Consulting Inc. now owns 2,405 shares of the company’s stock valued at $49,000 after acquiring an additional 2,382 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.